Insights

Gathering insights about GDT…

Similar companies to GDT

GDT Tech Stack

GDT uses 8 technology products and services including Fusion Ads, RSS, Chart.js, and more. Explore GDT's tech stack below.

Fusion Ads
Advertising
RSS
Content Management System
Chart.js
Javascript Graphics
jQuery Migrate
Javascript Libraries
Modernizr
Javascript Libraries
Priority Hints
Performance
Apache
Web Servers
TouchSwipe
Web Tools And Plugins

Media & News

CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why
CytoMed Therapeutics Limited (NASDAQ: GDTC - Get Free Report)'s stock price was up 7.2% on Thursday. The stock traded as high as $1.67 and last traded at $1.67. Approximately 32,493 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 78,542 shares. The stock had previously closed at $1.5573.
Dec 12, 2025 | www.defenseworld.net
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
CytoMed Therapeutics Limited (NASDAQ:GDTC ) Q2 2025 Earnings Call October 2, 2025 10:00 AM EDT Company Participants Yvonne Goh - Chief Financial Officer Presentation Yvonne Goh Chief Financial Officer Good morning and good evening, everyone. Can you hear me?
Oct 02, 2025 | seekingalpha.com
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce the publication of a preclinical study, in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shelf” Immunotherapy Approach”. The study results from this collaborative research with The University of Texas, MD Anderson Cancer Center (MDACC), are suggesting the promising potential of CytoMed's allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This collaboration with MDACC is under a previously announced research agreement in May 2023. The research article is now publicly and freely online at Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach.
Oct 02, 2025 | www.globenewswire.com
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce it has successfully expanded clinical-scale natural killer (“NK”) cells from cord blood units that have been cryopreserved for more than a decade. This sets the impetus for establishing a new business platform to generate additional revenue streams and future growth.
Aug 28, 2025 | www.globenewswire.com
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce that it entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. (the “Agent”), as the sales agent.
Aug 18, 2025 | www.globenewswire.com
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.
Jul 21, 2025 | www.globenewswire.com
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024 financial results and provided clinical and corporate updates.
Apr 28, 2025 | www.globenewswire.com

GDT's Email Address Formats

GDT uses at least 2 format(s):

GDT Email Formats	Example	Percentage
First.Last@gdt.com	John.Doe@gdt.com	61%
FLast@gdt.com	JDoe@gdt.com	17%
FirstLast@gdt.com	JohnDoe@gdt.com	4%
First-Last@gdt.com	John-Doe@gdt.com	2%
First@gdt.com	John@gdt.com	1%
Last.First@gdt.com	Doe.John@gdt.com	1%
FirstL@gdt.com	JohnD@gdt.com	1%
Last.F@gdt.com	Doe.J@gdt.com	1%
Last_First@gdt.com	Doe_John@gdt.com	1%
F.Last@gdt.com	J.Doe@gdt.com	1%
FirLast@gdt.com	JohDoe@gdt.com	1%
FirstLa@gdt.com	JohnDo@gdt.com	1%
LastFirst@gdt.com	DoeJohn@gdt.com	1%
First_L@gdt.com	John_D@gdt.com	1%
First.L@gdt.com	John.D@gdt.com	1%
LastFir@gdt.com	DoeJoh@gdt.com	1%
LastF@gdt.com	DoeJ@gdt.com	1%
First_Last@gdt.com	John_Doe@gdt.com	1%
F-Last@gdt.com	J-Doe@gdt.com	1%
LastFi@gdt.com	DoeJo@gdt.com	1%

Frequently Asked Questions

What is GDT's stock symbol?

GDT is a publicly traded company; the company's stock symbol is GDTC.

What is GDT's official website and social media links?

GDT's official website is gdt-rio.com.br and has social profiles on LinkedIn.

What is GDT's NAICS code?

GDT's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does GDT have currently?

As of December 2025, GDT has approximately 298 employees across 6 continents, including AsiaNorth AmericaEurope. Key team members include Head Coach Gdt Slough / Uxbridge Ltc: G. N.Account Manager: L. M.Account Manager: T. R.. Explore GDT's employee directory with LeadIQ.

What industry does GDT belong to?

GDT operates in the Medical Equipment Manufacturing industry.

What technology does GDT use?

GDT's tech stack includes Fusion AdsRSSChart.jsjQuery MigrateModernizrPriority HintsApacheTouchSwipe.

What is GDT's email format?

GDT's email format typically follows the pattern of First.Last@gdt.com. Find more GDT email formats with LeadIQ.

GDT

Q: What is GDT's official website and social media links?

GDT's official website is gdt-rio.com.br. GDT has social profiles on LinkedIn.

Q: How many employees does GDT have currently?

GDT has approximately 298 employees.

Q: What technology does GDT use?

GDT's tech stack includes Smash Balloon Instagram Feed, Apache, Twemoji, Apache HTTP Server, Lightbox.

Medical Equipment ManufacturingPennsylvania, United States201-500 Employees

Learn about working at GDT. Join LinkedIn today for free. See who you know at GDT, leverage your professional network, and get hired.

Company Overview

Website: gdt-rio.com.br
Stock Symbol: GDTC
NAICS Code: 3391 - Medical Equipment and Supplies Manufacturing
Employees: 201-500

Media & News

Funding & Financials

$100M$250M
GDT's revenue is estimated to be in the range of $100M$250M

Funding & Financials

$100M$250M
GDT's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to GDT

GV Centric

EDP

Teladata, LLC

GDT Tech Stack

Media & News

CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why

CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

GDT's Email Address Formats

Frequently Asked Questions

What is GDT's stock symbol?

What is GDT's official website and social media links?

What is GDT's NAICS code?

How many employees does GDT have currently?

What industry does GDT belong to?

What technology does GDT use?

What is GDT's email format?

GDT

Company Overview

Media & News

CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why

CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?